Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 9/20 | 0.76 |
| ▸ | PIM2 | Q9P1W9 | 9/20 | 0.76 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.58 |
| ▸ | HPGD | P15428 | 4/20 | 0.57 |
| ▸ | MAOA | P21397 | 2/20 | 0.56 |
| ▸ | MAOB | P27338 | 2/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.56 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2546790 | 1.00 | PIM1 (0.76) | PIM1PIM2AKR1B1NPC1RAB9A | |
| SCHEMBL2547571 | 0.87 | PIM1 (0.80) | PIM1PIM2AKR1B1MAOAMAOB | |
| SCHEMBL2547569 | 0.87 | PIM1 (0.80) | PIM1PIM2AKR1B1MAOAMAOB | |
| SCHEMBL2541053 | 0.87 | PIM1 (1.00) | PIM1PIM2AKR1B1NPC1RAB9A | |
| SCHEMBL2541054 | 0.87 | PIM1 (1.00) | PIM1PIM2AKR1B1NPC1RAB9A | |
| SCHEMBL2541051 | 0.87 | PIM1 (1.00) | PIM1PIM2AKR1B1NPC1RAB9A | |
| SCHEMBL2542103 | 0.84 | PIM1 (0.78) | PIM1PIM2AKR1B1NPC1RAB9A | |
| SCHEMBL2542102 | 0.84 | PIM1 (0.78) | PIM1PIM2AKR1B1NPC1RAB9A | |
| SCHEMBL2544242 | 0.84 | PIM1 (0.78) | PIM1PIM2AKR1B1NPC1RAB9A | |
| SCHEMBL2544241 | 0.84 | PIM1 (0.78) | PIM1PIM2AKR1B1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263664-A1 | Inhibitors of PIM-1 Protein Kinases, Compositions and Methods for Treating Prostate Cancer | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2011-10-27 | — | — | US | claimed |
| US-20110263664-A1 | Inhibitors of PIM-1 Protein Kinases, Compositions and Methods for Treating Prostate Cancer | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263664-A1 | Inhibitors of PIM-1 Protein Kinases, Compositions and Methods for Treating Prostate Cancer | PIM1, PIM2, PIM3 | PIM1 1/4885PIM2 2/4885AKR1B1 3892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.